Literature DB >> 7527506

Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy.

T Ogawa1, N Yorioka, M Yamakido.   

Abstract

To investigate the involvement of vitronectin, the terminal complement complex (C5b-9), and the vitronectin receptor in the pathogenesis of membranous nephropathy, the immunohistochemical localization of these antigens in the kidney was determined using the immunoperoxidase method and monoclonal antibodies: antivitronectin, anti-SC5b-9 (neoantigen), and antivitronectin receptor (specific for alpha v beta 3 and alpha v). The subjects were 6 patients with membranous nephropathy, and the controls were 2 patients with minimal-change nephrotic syndrome. In membranous nephropathy, vitronectin was localized in subepithelial deposits and in epithelial cell foot processes and was intensely positive in the foot processes adjacent to subepithelial deposits. C5b-9 showed a similar pattern of localization to vitronectin. Both alpha v beta 3 and alpha v were localized in the basal portions of the foot processes of visceral epithelial cells as well as along the borders of these cells adjacent to the urinary space. Deposition at the former site was heavier than at the latter, and localization was especially prominent adjacent to the subepithelial deposits. In addition, alpha v was localized around and within some of the electron-lucent subepithelial deposits in the basement membrane. In contrast, the deposition of vitronectin, C5b-9, alpha v beta 3, and alpha v was always less intense in minimal-change nephrotic syndrome than in membranous nephropathy. Vitronectin and C5b-9 were localized to small parts of mesangium and glomerular basement membrane, while alpha v beta 3 and alpha v deposits showed no difference in intensity between the basal portions of the foot processes and the urinary border of the visceral epithelial cells. Thus, membranous nephropathy featured increased localization of vitronectin, C5b-9, and vitronectin receptors both within and around the subepithelial deposits, suggesting that the mechanism of immune complex disposal via the vitronectin receptor and the vitronectin-C5b-9 complex, associated with complement activation due to subepithelial immune complex formation, may also be active.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527506     DOI: 10.1159/000188225

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

2.  Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC).

Authors:  A K Chauhan; T L Moore
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

3.  Expanding the family of extracellular chaperones: Identification of human plasma proteins with chaperone activity.

Authors:  Nicholas J Geraghty; Sandeep Satapathy; Megan Kelly; Flora Cheng; Albert Lee; Mark R Wilson
Journal:  Protein Sci       Date:  2021-10-04       Impact factor: 6.725

Review 4.  Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

Authors:  Jacob J E Koopman; Mieke F van Essen; Helmut G Rennke; Aiko P J de Vries; Cees van Kooten
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

5.  Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin.

Authors:  Thuzar M Shin; J Mario Isas; Chia-Ling Hsieh; Rakez Kayed; Charles G Glabe; Ralf Langen; Jeannie Chen
Journal:  Mol Neurodegener       Date:  2008-10-21       Impact factor: 14.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.